Clinical trials
Colorectal Cancer Liver Metastasis clinical trials
Below are recruiting colorectal cancer liver metastasis clinical trials, each written for real people, not researchers. We’re tracking 179 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05007132RecruitingPhase 2
First-line metastatic colon or rectal cancer study with targeted drugs
This Phase 2 trial compares two treatment combinations as a first treatment for metastatic (spread) colon or rectal cancer. It looks to see whether one combo works better or is safer than the other.
BerlinAges 18 years+ - NCT05068531Recruiting
Detecting early treatment failure in stage IV colon cancer
This study looks for early signs that treatment is not working in people with stage IV colon or rectal cancer that has spread only to the liver. It may help doctors adjust care sooner by using regular blood, stool, and tissue samples around liver procedures.
Montreal, QuebecAges 18 years+ - NCT06446050RecruitingEarly Phase 1
Modified stem cells for advanced colorectal cancer
This trial tests a new treatment using special stem cells (modified to boost your immune system) for people with advanced colorectal cancer. It is for patients who are 18 or younger and whose cancer has not responded to or cannot be treated with standard therapies.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07790510RecruitingPhase 1/Phase 2
Study of HSK42360 with cetuximab for BRAF-mutated colorectal cancer
This trial tests an experimental drug (HSK42360-Na) combined with standard treatments (cetuximab with or without chemotherapy) for people with advanced colorectal cancer that has a specific BRAF mutation. The goal is to see if this combination can shrink tumors or slow their growth, and to check its safety.
BeijingAges 18 years+ - NCT06341296RecruitingPhase 2
Irinotecan liposomes for first-line advanced colorectal cancer
This trial tests a new type of chemotherapy (irinotecan liposomes) as a first treatment for metastatic colorectal cancer that has not been treated before. It focuses on patients with specific genetic changes (RAS or BRAF V600E mutation) or right-sided colon cancer, and looks at how well the drug works.
Sichuan, Sichuan, ChengduAges 18–85 - NCT06547203RecruitingPhase 2
Cetuximab, irinotecan, and toripalimab for right-sided colorectal cancer
This trial tests a combination of three drugs (cetuximab, irinotecan, and toripalimab) for people with advanced right-sided colon cancer that does not have certain gene mutations. It's for those whose cancer has gotten worse after standard treatments.
Guangzhou, GuangdongAges 18–80 - NCT06563986RecruitingPhase 2
Combination therapy for advanced colorectal cancer in the liver
This trial tests a combination of two chemotherapy drugs (FTD and tipiracil), a targeted therapy (bevacizumab), and a radiation treatment (radioembolization) for people with colorectal cancer that has spread mainly to the liver and hasn't responded to other treatments. The goal is to see if this combination can shrink tumors and help control the cancer.
UtrechtAges 18 years+ - NCT05462613RecruitingPhase 2/Phase 3
Regorafenib plus aspirin then standard chemo for metastatic bowel cancer
This trial tests whether adding regorafenib and low-dose aspirin before standard chemotherapy can slow metastatic colorectal cancer after it has progressed on prior treatment. It may help by trying a different cancer-fighting approach earlier, followed by the usual chemo plan.
BesançonAges 18 years+ - NCT06425133RecruitingPhase 2
Regorafenib plus low-dose chemo for advanced colorectal cancer
This trial tests a combination of regorafenib (a targeted pill that cuts off blood supply to tumors) with a low-dose, continuous chemotherapy regimen for people whose colorectal cancer has spread and is no longer responding to standard treatments. The goal is to see if this mix can slow or stop the cancer's growth.
AuxerreAges 18 years+ - NCT07504523RecruitingPhase 1
Personalized T-cell therapy for advanced colorectal cancer
This trial tests a custom-made T-cell treatment designed to target unique markers on your tumor. It's for people with advanced colorectal cancer who have run out of standard options or can't take them, and it aims to shrink tumors and improve survival.
Hangzhou, ZhejiangAges 18–70 - NCT07389265RecruitingPhase 3
Continuing cetuximab after first treatment stops working for metastatic colorectal cancer
This trial tests if continuing the targeted therapy cetuximab after initial treatment stops working can help people with advanced colorectal cancer. Participants have a specific gene profile (RAS and BRAF normal) and their cancer responds well at first.
AnconaAges 18 years+ - NCT07381764RecruitingPhase 2
Rechallenge with targeted drugs for certain colorectal cancers
This study tests a new approach for people with a specific type of metastatic colorectal cancer that has stopped responding to initial treatments. It compares reusing a targeted drug combination (irinotecan plus cetuximab) versus a different chemotherapy plus a targeted drug (trifluridine/tipiracil plus bevacizumab) to see which works better for patients whose tumors have a certain genetic profile.
AlessandriaAges 18 years+ - NCT05093907RecruitingPhase 1/Phase 2
Testing a new cancer drug plus capecitabine for metastatic colon cancer
This trial studies whether BEY1107, a new treatment, is safe and works better when combined with capecitabine in people with metastatic colorectal (colon/rectum) cancer. It is aimed at cancers that have already progressed after standard chemotherapy.
Seoul, Jongro-goAges 19 years+ - NCT05299840Recruiting
Test a device to choose the first chemo for metastatic colon cancer
This study tests whether using the Oncogramme® device to guide the first-line treatment improves care for people with metastatic colorectal (colon/rectum) cancer. If the device helps pick the most suitable standard chemotherapy plan, it could lead to better outcomes than choosing without it.
MarseilleAges 18 years+ - NCT06869096Recruiting
Flushing liquid during colorectal cancer surgery
This trial compares two different liquids used to flush the surgical area during colorectal cancer surgery to see which one better prevents infections. If you are having surgery for colorectal cancer, you may be able to join.
Nanchong, SichuanAges 18–85 - NCT06792695RecruitingPhase 2
Study of new treatments for colorectal cancer
This trial tests new treatment combinations for colorectal cancer that has spread (metastatic). It is for people whose cancer is mismatch repair proficient (pMMR) or microsatellite stable (MSS) and who have not had previous treatment for metastatic disease.
Scottsdale, ArizonaAges 18–130 - NCT05959356RecruitingPhase 2
First-line treatment for left-sided metastatic colon cancer with specific tumor markers
This Phase 2 trial tests a combination of medicines (cetuximab, envafolimab, and chemotherapy) as the first treatment for certain left-sided metastatic colorectal cancers. It may help by slowing or shrinking the cancer in people whose tumor has no RAS/BRAF mutations and is microsatellite-stable (MSS).
Foshan, GuangdongAges 18 years+ - NCT02732860Recruiting
Test your tumor’s drug response using a lab model
This trial grows a lab model from your own tumor tissue (or resected tissue) to predict which drugs might work best. It’s meant to match investigational treatments to your specific tumor biology.
Toronto, OntarioAges 18 years+ - NCT07227636RecruitingPhase 2
Immunotherapy for ctDNA-positive colorectal cancer after surgery
This trial tests two immunotherapy drugs, botensilimab and balstilimab, for people with colorectal cancer who have had surgery and chemotherapy but still have detectable cancer DNA in their blood. The goal is to see if these drugs can help clear the remaining cancer cells.
Basking Ridge, New JerseyAges 18 years+ - NCT05991102Recruiting
Radiofrequency treatment with Lonsurf and Avastin for advanced colorectal cancer
This trial tests if adding a special radiofrequency treatment to the drugs Lonsurf (TAS-102) and Avastin (bevacizumab) can help people whose colorectal cancer has spread to the liver and has not responded to previous treatments. It is for patients with limited options who have already tried at least two standard chemotherapy regimens.
BerlinAges 18 years+ - NCT06530303RecruitingPhase 1/Phase 2
Personalized immune cell therapy for colorectal cancer
This trial tests a treatment made from your own immune cells (called TILs) that are taken from your tumor, grown in a lab, and given back to you along with immunotherapy. It is for people with advanced colon or rectum cancer who have run out of standard options.
Beijing, Beijing MunicipalityAges 16–90 - NCT04929223RecruitingPhase 1
Targeted drug study for metastatic colon or rectal cancer
This Phase 1 study tests targeted cancer treatments in people with metastatic colorectal cancer, using genetic “biomarker” results to match you to the right treatment group. It focuses first on safety, and also looks for early signs the treatment may work in specific tumor subgroups.
Birmingham, AlabamaAges 18 years+ - NCT06525428RecruitingPhase 2
Adding radiation and immunotherapy to standard care for advanced colorectal cancer
This trial is testing a combination of standard chemotherapy, radiation therapy, and an immunotherapy drug (toripalimab) for people with metastatic colorectal cancer. It aims to see if adding radiation therapy and immunotherapy can help shrink tumors and improve outcomes.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07510308RecruitingPhase 1
Vaccine trial for advanced colorectal cancer
This trial tests a personalized vaccine made from your own tumor cells for advanced colorectal cancer that is mismatch repair proficient (pMMR). It aims to see if the vaccine can help when standard treatments have stopped working.
Chengdu, SichuanAges 18–75
Hear when a new Colorectal Cancer Liver Metastasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for colorectal cancer liver metastasis?
- Yes. Clin2 currently lists 179 recruiting colorectal cancer liver metastasis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a colorectal cancer liver metastasis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a colorectal cancer liver metastasis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.